Loading
All three of the active bowel cancer chemotherapy drugs given together instead of two. It shrinks more tumours than a doublet and is chosen when shrinking the tumour is what matters, usually with bevacizumab.
FOLFOXIRI combines infusional fluorouracil and leucovorin with both oxaliplatin and irinotecan every fourteen days, most often with bevacizumab. TRIBE showed that FOLFOXIRI plus bevacizumab gives a longer progression-free survival (12.1 against 9.7 months) and a higher response rate (65 against 53 percent) than FOLFIRI plus bevacizumab in untreated metastatic disease, and TRIBE2 showed the advantage survives as a strategy, with progression-free survival 2 of 19.2 against 16.4 months against a planned sequence of doublets. CAIRO5 found it the best induction for right-sided or RAS/BRAF-mutant liver-limited disease. The price is toxicity: grade 3 or 4 neutropenia in about half of patients, and more diarrhoea, stomatitis and neuropathy, so it is reserved for fit patients under about 75 with good performance status. In practice it is used when deep response matters most, to convert unresectable liver metastases, in BRAF V600E disease before the targeted triplet was available, and in young patients with heavy disease burden. Induction is usually limited to eight to twelve cycles followed by fluoropyrimidine and bevacizumab maintenance.
1.Oxaliplatin forms platinum adducts that crosslink the two strands of DNA
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (grade 3-4) 50 percent in the TRIBE2 experimental arm against 21 percent with a doublet | - | 50% |
| Diarrhoea (grade 3-4) | - | 17% |
| Peripheral sensory neuropathy Cumulative, from oxaliplatin | - | - |
| Stomatitis | - | - |
Rates read from the source. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"FOLFOXIRI" OR ABSTRACT:"FOLFOXIRI" OR TITLE:"5-FU, leucovorin, oxaliplatin, irinotecan" OR ABSTRACT:"5-FU, leucovorin, oxaliplatin, irinotecan" OR TITLE:"mFOLFOXIRI" OR ABSTRACT:"mFOLFOXIRI") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), not a curated reading list.
Shares UGT1A1, Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Fluorouracil (5-FU).
Shares CAIRO5, Leucovorin (folinic acid), Oxaliplatin, Fluorouracil (5-FU).
Shares UGT1A1, Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Fluorouracil (5-FU).
Shares Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Oxaliplatin, Fluorouracil (5-FU).
Shares Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads).
Shares Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Oxaliplatin, Fluorouracil (5-FU).
Shares Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Oxaliplatin, Fluorouracil (5-FU).
Shares Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads).